US/UK/Canada

Share

Quotes

This project with Amicogen is incredibly interesting and creates very good conditions for a deeper collaboration in the future. With this agrement, Amicogen and Bio-Works will establish the first local production of agarose-based resins in South Korea
says Jonathan Royce, CEO at Bio-Works Technologies.
Pick a time period -
Tags ( Active)

Letter of Intent for order of WorkBreads affimAb increased to 11,9 Mkr

Bio-Works Technologies AB is pleased to announce that the Letter of Intent (LOI) we received earlier this month has increased. The new anticipated order value is 11,9 Mkr.“We are excited about this development as it underscores the value Bio-Works provides to our customers” said Lone Carlbom, CEO of Bio-Works. “We are very proud about the trust that the customer puts in us by designing our product into several manufacturing processes.”

Bio-Works comfirms an order from Nemysis Ltd worth 2.2 MSEK

Bio-Works confirmed a new order of WorkBeads NiMAC, to Nemysis Ltd, an Irish developer of bioactive substances designed to target nutritional disorders and deficiencies. The order, worth approximately 2.2 MSEK, will enable Nemysis to scale-up one of its programs to minimize gastrointestinal disorders."Bio-Works is very pleased to be able to support Nemysis in its mission to create products which prevent the negative side effects of nutrient disorders and deficiency," said Lone Carlbom, CEO of Bio-Works Technologies. “This order is evidence that our strategy to create unique purification

Bio-Works receives a Letter of Intent (LOI) - the anticipated order value is €652,000.

Bio-Works Technologies AB is pleased to announce that it has received a Letter of Intent (LOI) for a significant order of WorkBeads™ affimAb, used in manufacturing processes of vaccines. The anticipated order value is €652,000.This LOI marks a pivotal step toward reinforcing Bio-Works’ relationship with our customers in the biopharmaceutical industry. Bio-Works’ WorkBeads  affimAb product has shown exceptional value in high-stakes manufacturing environments, with data from multiple manufacturing sites affirming its performance. “We are thrilled about the potential of this order, as it

Bio-Works receives a Letter of Intent (LOI) - the anticipated order value is €652,000.

Bio-Works Technologies AB is pleased to announce that it has received a Letter of Intent (LOI) for a significant order of WorkBeads™ affimAb, used in manufacturing processes of vaccines. The anticipated order value is €652,000.This LOI marks a pivotal step toward reinforcing Bio-Works’ relationship with our customers in the biopharmaceutical industry. Bio-Works’ WorkBeads  affimAb product has shown exceptional value in high-stakes manufacturing environments, with data from multiple manufacturing sites affirming its performance. “We are thrilled about the potential of this order, as it

Bio-Works publishes half year report 2024

The first half in review Jan – Jun 2024 · Net sales decreased 41% to 13,0 MSEK (22,1) with. Sales in North America has been weak during the first half, while European sales have been somewhat stronger. We are looking forward to stronger sales in the second half, as a result of increased order intake. · Order intake increased by 16% to 18,3 MSEK (15,9). · Net profit for the first half was -18,9 MSEK (-28,8). The improvement can be explained by the cost reduction program, improved gross margins and lower OPEX. · Earnings per share in the first half of the year amounted to -0,

Bio-Works Technologies AB has been approved for listing on Spotlight Stock Market before planned and fully secured rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW.Bio-Works Technologies AB (”Bio-Works” or ”the Company””) appounces that the Company has been approved for listing on Spotlight Stock Market. The first day of trade

Bio-Works Technologies resolves on fully secured rights issue of approximately SEK 39 million and announces intention to change listing venue to Spotlight Stock Market

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW.The Board of Directors of Bio-Works Technologies AB ("Bio-Works" or the "Company") has today resolved on a new issue of shares and warrants ("Units") with

Bio-Works and Amicogen have concluded their technology transfer project.

Bio-Works Technologies and Amicogen Inc. of South Korea have concluded their mutual technology transfer project allowing Amicogen to establish local production of agarose resins in South Korea.As a result, Bio-Works and Amicogen have settled outstanding payables from Bio-Works with outstanding receivables from Amicogen. The agreement was made public in a press release dated February 17, 2021 in which Bio-Works announced the signing of the licensing agreement with Amicogen. ContactsFor more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge,

Bio-Works receives an additional order worth SEK 2.6 million for WorkBeads

Bio-Works has received another order from a production customer in India who placed an order earlier this year. The latest order for Work Beads is worth SEK 2.6 million. The customer is a manufacturer of bio-therapeutics."This proves that Bio-Works’ production customers value our products and customer service very highly, and that our efforts to design-in WorkBeads resins in production-scale processes is producing lasting results" said Lone Carlbom, CEO of Bio-Works. ContactsFor more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-

Bio-Works Chairman Peter Ehrenheim: “Significant Changes for Success and Profitability”

At Bio-Works’ Annual General Meeting on May 24, Chairman of the Board Peter Ehrenheim addressed the company’s shareholders and employees with an evaluation of the company’s operations and future direction:“It is no secret that Bio-Works has not developed according to the expectations set by the board  over the past year. We have faced several challenges that have affected upon our growth and profitability”, said Ehrenheim. He emphasized that despite these challenges, the board strongly believes in Bio-Works’ business-idea and its potential for success. Ehrenheim highlighted: “Bio-Works

Communiqué from Bio-Works Technologies’ annual general meeting 2024

Bio-Works Technologies’ annual general meeting was held 24 May 2024. The following resolutions were made at the annual general meeting, among other resolutions.The meeting adopted the income statement and balance sheet and the consolidated income statement and consolidated balance sheet for the financial year 2023. The meeting resolved that no dividend shall be paid for the financial year 2023.The meeting granted the board members and CEO discharge from liability for the financial year 2023.The meeting resolved that the number of board members shall be five and re-elected Peter von

Lone Carlbom Assumes Role as CEO of Bio-Works

Effective today, Lone Carlbom has assumed the role of CEO of Bio-Works. Concurrently, the company's CEO to date, Jonathan Royce, has resigned from his position in consultation with Bio-Works’ Board of Directors, effective immediately.Lone Carlbom Assumes Role as CEO of Bio-WorksEffective today, Lone Carlbom has assumed the role of CEO of Bio-Works. Concurrently, the company's CEO to date, Jonathan Royce, has resigned from his position in consultation with Bio-Works’ Board of Directors, effective immediately.In line with the CEO transition, Bio-Works’ management team is intended to be

Bio-Works receives an additional order worth SEK 2.9 million for WorkBeads

Bio-Works has received another order from a production customer in the Netherlands who placed two orders earlier this year. The latest order is worth SEK 2.9 million. The customer is a global manufacturer of active pharmaceutical ingredients (API) with approximately 1,800 employees."This is further evidence that Bio-Works’ production customers value our products and customer service very highly," said Jonathan Royce, CEO of Bio-Works. "Our continuous efforts to expand business with existing customers who have already approved Bio-Works as a supplier are bearing fruit. At the same time, we

Change in the nomination committee's proposal regarding election of board members of Bio-Works

The Nomination Committee's proposal for the election of board members was reported in the notice for Bio-Works' Annual General Meeting, which was announced via a press release on April 23, 2024. Johan Sedihn has since informed that he has declined re-election at the Annual General Meeting. The Nomination Committee has now informed the company that it has decided to supplement the proposal with the nomination of an additional member, Thomas Gür.Thomas Gür was born in 1959 and has over 40 years of experience in the areas of communication, investor relations, media handling, and public

Correction: Bio-Works reports first quarter 2024

Information about the company's cash position was omitted in the original release Today, Bio-Works Technologies announced net sales for the first quarter amounted to 6.1 MSEK, a 20% decrease versus the same period in 2023.The first quarter in review · Order intake amounted to 6.2 MSEK, a 44% decrease versus the same period in 2023. · Order backlog at the end of the period amounted to 4.6 MSEK. · Operating expenses (excluding raw materials) amounted to 17.1 MSEK, in-line with the company’s operating plan estimate for the first quarter. · The company’s cash position at the

Bio-Works reports first quarter 2024

Today, Bio-Works Technologies announced net sales for the first quarter amounted to 6.1 MSEK, a 20% decrease versus the same period in 2023.The first quarter in review · Order intake amounted to 6.2 MSEK, a 44% decrease versus the same period in 2023. · Order backlog at the end of the period amounted to 4.6 MSEK. · Operating expenses (excluding raw materials) amounted to 17.1 MSEK, in-line with the company’s operating plan estimate for the first quarter. “Order intake has been much weaker expected during the first quarter of the year. We continue to focus all our efforts to

Bio-Works appeals case to Supreme Administrative Court

Bio-Works Technologies AB has been subjected to a tax surcharge of 2.0 MSEK following a decision by the Swedish Tax Agency. The decision by the Administrative Court on August 22, 2023, was appealed to the Court of Appeal on September 19, 2023. The Court of Appeal made the same judgement as the Administrative Court and the Swedish Tax Agency in a verdict on March 25, 2024. The company has now appealed the Court of Appeal’s ruling to the Supreme Administrative Court. The company’s assessment is that the Supreme Administrative Court will approve the further appeal. The company’s stance

Bio-Works confirms new order from Indian bio-therapeutic manufacturer worth 3.1 MSEK

Today, Bio-Works Technologies AB has confirmed a production-scale order worth 3.1 MSEK to an Indian manufacturer of bio-therapeutics. This order is a repeat order from a customer which first started using Bio-Works’ products in 2021.“Bio-Works prides itself on delivering high-quality products and maintaining strong customer relations. This repeat order is evidence that our efforts to design-in WorkBeads resins in production-scale processes is producing lasting results,” said Jonathan Royce, CEO at Bio-Works. The company that placed the order is a bio-therapeutics manufacturer with

Bio-Works publishes year end report for January-December 2023

A challenging year for biotech and for Bio-Works July – December 2023 · Net sales decreased by 6% to 21.8 (23.2) MSEK. Sales in Europe continued to be strong in the second half as a result of orders made prior to the period. The economic slow-down in North America had a negative impact on sales in the period. · Order intake* decreased by 70% to 10.2 (34.3) MSEK. The economic slow-down in our main markets has made some of our customers delay production and investments in new projects. The distribution of orders over Q3 and Q4 was 2.8 MSEK and 7.4 MSEK, respectively. · Profit in

Bio-Works expands product range with introduction of WorkBeads 40 Butyl SH

WorkBeads 40 Butyl SH is a pioneering hydrophobic interaction chromatography (HIC) resin for purification of plasmids, proteins, peptides, and oligonucleotidesToday, Bio-Works, a trailblazer in purification solutions, is thrilled to announce the addition of WorkBeads™ 40 Butyl SH to its product portfolio. This revolutionary hydrophobic interaction chromatography (HIC) resin is designed for research and industrial-scale purification of proteins, peptides, plasmids, and oligonucleotides. This launch marks a significant expansion of Bio-Works' product range. Advantages of WorkBeads 40 Butyl

The nomination committee’s proposal regarding election of board members of Bio-Works

The Nomination Committee for Bio-Works Technologies has resolved to submit the following proposal regarding election of the Board of Directors to the Annual General Meeting of Bio-Works on May 24, 2024. · The Board of Directors shall consist of five members (four at present) · Re-election of Peter Ehrenheim, Kirsti Gjellan, Johan Sedihn and Peter Nählstedt as Board members · Election of Jonas Ahlén, CEO of Bonit Capital, as new member of the Board of Directors · Re-election of Peter Ehrenheim as Chairman of the Board The Nomination Committee resolved to propose PWC, with

Bio-Works receives second order worth 2.4 MSEK order from customer in Netherlands

Bio-Works has received a second order from the same production customer in Netherlands who ordered last week. The second order is worth 2.4 MSEK. The order is a scale-up order for a project to which Bio-Works has previously delivered at R&D scale. The customer is a global manufacturer of active pharmaceutical ingredients (APIs) with approximately 1,800 employees.“We are very happy to have received this second order from a customer who has previously had good experience withWorkBeads Q resin for anion exchange chromatography and is now scaling-

Correction: Bio-Works receives repeat order worth 2.4 MSEK order for WorkBeads resin

The original press release stated that the order value was 1.9 MSEK, but the actual order value is 2.4 MSEK. Bio-Works has received a new order from a production customer in the Netherlands worth 2.4 MSEK. The order is a repeat order for a project to which Bio-Works has previously delivered. The customer is a global manufacturer of active pharmaceutical ingredients (APIs) with approximately 1,800 employees.“We are very happy to have received this repeat order from a customer who we have been working with for many years. The suitability of WorkBeads in large-scale manufacturing is one of

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe